(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 28 June 2001 (28.06.2001)

PCT

(10) International Publication Number WO 01/46194 A2

(51) International Patent Classification⁷: C07D 487/04, 237/08, C07C 317/14, A61P 29/00

(21) International Application Number: PCT/EP00/13001

(22) International Filing Date:

20 December 2000 (20.12.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 9930358.8

22 December 1999 (22.12.1999) GF

(71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MATHEWS, Neil [GB/GB]; Glaxo Wellcome PLC, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). WARD, Richard, Anthony [GB/GB]; Glaxo Wellcome PLC, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). WHITEHEAD, Andrew, Jonathan [GB/GB]; Glaxo Wellcome PLC, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB).

(74) Agent: LANE, Graham; Glaxo Wellcome PLC, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published:

 Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR THE PREPARATION OF PYRAZOLOPYRIDAZINE DERIVATIVES





(57) Abstract: The invention provides a process for preparing a compound of formula (I) and pharmaceutically acceptable derivatives thereof in which: Ro is halogen, C1-6alkyl, C1-6alkoxy, C₁₋₆alkoxy substituted by one or more fluorine atoms, or O(CH₂)_nNR⁴R⁵; R¹ and R² are independently selected from H, C_{1-6} alkyl, $C_{i,1}$ -6; alkyl substituted by one or more fluorine atoms, C₁₋₆alkoxy, C₁₋₆hydroxyalkyl, SC₁₋₆alkyl, C(O)H, C(O)C₁₋₆alkyl, C₁₋₆alkylsulphonyl, C₁₋₆alkoxy substituted by one or more fluorine atoms, $O(CH_2)_nCO_2C_{1-6}$ alkyl, $O(CH_{2n}SC_{1-6}$ alkyl, $(CH_2)_nNR^4R^5$, (CH₂)_nSC₁₋₆alkyl or C(O)NR⁴R⁵; with the proviso that when R⁰ is at the 4-position and is halogen, at least one of R1 and R2 is C₁₋₆alkylsulphonyl, C₁₋₆alkoxy substituted by one or more fluorine atoms, O(CH₂)_nCO₂C₁₋₆alkyl, O(CH₂)_nSC₁₋₆alkyl, (CH₂)_nNR⁴R⁵ or (CH₂)_nSC₁₋₆alkyl, C(O)NR⁴R⁵; R³ is C₁₋₆alkyl or NH₂; R⁴ and R5 are independently selected from H, or C1-6alkyl or, together with the nitrogen atom to which they are attached, form a 4-8 membered saturated ring; and n is 1-4; which comprises oxidising a corresponding compound of formula (II) or an isomer thereof.



WO 01/46194 A2

PROCESS FOR THE PREPARATION OF PYRAZOLOPYRIDAZINE DERIVATIVES

This invention relates to a process for the preparation of pyrazolopyridazine derivatives and to intermediates for use therein.

5 Pyrazolopyridazine derivatives of formula (I)

$$R^3O_2S$$
 R^1
 R^2
 $N-N$
 N
 N
 N
 N

and pharmaceutically acceptable derivatives thereof in which:

 R^0 is halogen, $C_{\text{1-6}}alkyl,\ C_{\text{1-6}}alkoxy,\ C_{\text{1-6}}alkoxy$ substituted by one or more fluorine atoms, or $O(CH_2)_nNR^4R^5;$

 R^1 and R^2 are independently selected from H, C_{1-6} alkyl, C_{1-6} alkyl substituted by one or more fluorine atoms, C_{1-6} alkoxy, C_{1-6} hydroxyalkyl, SC_{1-6} alkyl, C(O)H, $C(O)C_{1-6}$ alkyl, C_{1-6} alkylsulphonyl, C_{1-6} alkoxy substituted by one or more fluorine atoms, $O(CH_2)_nCO_2C_{1-6}$ alkyl, $O(CH_2)_nSC_{1-6}$ alkyl, $O(CH_2)_nNR^4R^5$, $O(CH_2)_nSC_{1-6}$ alkyl or $O(C)NR^4R^5$; with the proviso that when O(C)0 is at the 4-position and is halogen, at least one of O(C)1 and O(C)2 is O(C)3 is O(C)4.6 alkylsulphonyl, O(C)5 is at the 4-position and is halogen, at least one of O(C)4 and O(C)5 is O(C)6.7 alkylsulphonyl, O(C)7 alkylsulphonyl, O(C)8 is O(C)8.7 alkylsulphonyl, O(C)9 alkyl, O(C)9

 R^3 is C_{1-6} alkyl or NH_2 ;

10

15

20

25

 R^4 and R^5 are independently selected from H, or C_{1-6} alkyl or, together with the nitrogen atom to which they are attached, form a 4 - 8 membered saturated ring; and n is 1-4;

are disclosed in international patent application publication no. WO99/12930, incorporated herein by reference.

By pharmaceutically acceptable derivative is meant any pharmaceutically acceptable salt, solvate or ester, or salt or solvate of such ester, of the compounds of formula (I), or any other compound which upon administration to

the recipient is capable of providing (directly or indirectly) a compound of formula (I) or an active metabolite or residue thereof.

It will be appreciated that, for pharmaceutical use, the salts referred to above will be the physiologically acceptable salts, but other salts may find use, for example in the preparation of compounds of formula (I) and the physiologically acceptable salts thereof.

Suitable pharmaceutically acceptable salts of the compounds of formula (I) include acid addition salts formed with inorganic or organic acids, preferably inorganic acids, e.g. hydrochlorides, hydrobromides and sulphates.

The term halogen is used to represent fluorine, chlorine, bromine or iodine.

The term 'alkyl' as a group or part of a group means a straight or branched chain alkyl group, for example a methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl or t-butyl group.

The compounds of formula (I) are potent and selective inhibitors of COX-2.

They are of interest for use in human and veterinary medicine, particularly in the treatment of the pain (both chronic and acute), fever and inflammation of a variety of conditions and diseases.

Several processes for the preparation of the compounds of formula (I) are disclosed in WO99/12930.

The present invention provides a particularly advantageous process of preparing compounds of formula (I), not hitherto specifically disclosed, which comprises oxidation of a corresponding dihydro-pyrazolopyridazine.

15

20

3

Accordingly, in a first aspect, the instant invention provides a process for the preparation of a compound of formula (I) which comprises oxidising under conventional conditions a compound of formula (II)

$$R^3O_2S$$
 $N-N$
 N
 N
 N

5 wherein R^0 to R^3 are as defined for formula (I).

Conveniently the oxidation is effected in a solvent, such as a halogenated alkane (e.g. dichloromethane); at ambient to elevated temperature, such as from 20°C to reflux (e.g. at about 25 °C); and in the presence of a catalyst, such as activated carbon, or a transition metal catalyst (e.g. palladium on activated carbon). Alternatively, the catalyst may be replaced by an oxidising agent, such as a source of oxygen (e.g. air), or iodine.

The process according to the invention is surprisingly advantageous, being easy to carry out and proceeding in good yield.

As will be appreciated by those skilled in the art, the preparation of pharmaceutically acceptable derivatives of formula (I) may conveniently be effected by a process which comprises oxidising under conventional conditions a corresponding derivative of formula (II).

In another aspect the invention provides a process for preparing a compound of formula (I) where R⁰ is at the 3- or 4-position of the phenyl ring, as defined in formula (I).

In another aspect the invention provides a process for preparing a compound of formula (I) where R¹ is at the 6-position of the pyridazine ring, as defined in formula (I).

In another aspect the invention provides a process for preparing a compound of formula (I) where R^0 is F, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} alkoxy substituted by one or more fluorine atoms, or $O(CH_2)_{1-3}NR^4R^5$; or, more preferably, R^0 is F, C_{1-3} alkoxy or C_{1-3} alkoxy substituted by one or more fluorine atoms.

In another aspect the invention provides a process for preparing a compound of formula (I) where R¹ is C₁₋₄alkylsulphonyl, C₁₋₄alkoxy substituted by one or more fluorine atoms, O(CH₂)₁₋₃CO₂C₁₋₄alkyl, O(CH₂)₁₋₃SC₁₋₄alkyl, (CH₂)₁₋₃NR⁴R⁵, (CH₂)₁₋₃SC₁₋₄alkyl or C(O)NR⁴R⁵ or, when R⁰ is C₁₋₆alkyl, C₁₋₆alkoxy, O(CH₂)_nNR⁴R⁵, may also be H; or, more preferably, R¹ is C₁₋₄alkylsulphonyl, C₁₋₄alkoxy substituted by one or more fluorine atoms or, when R⁰ is C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkoxy substituted by one or more fluorine atoms, or O(CH₂)_nNR⁴R⁵, may also be H.

In another aspect the invention provides a process for preparing a compound of formula (I) where R^2 is H.

In another aspect the invention provides a process for preparing a compound of formula (I) where R³ is methyl or NH₂.

In another aspect the invention provides a process for preparing a compound of formula (I) where R^4 and R^5 are independently C_{1-3} alkyl or, together with the nitrogen atom to which they are attached, form a 5 - 6 membered saturated ring.

In another aspect the invention provides a process for preparing a compound of formula (I) where n is 1 - 3, more preferably 1 or 2.

25

30

In another aspect the invention provides a process for preparing one group of compounds of formula (I) (group A) wherein: R^0 is F, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} alkoxy substituted by one or more fluorine atoms, or $O(CH_2)_nNR^4R^5$; R^1 is C_{1-4} alkylsulphonyl, C_{1-4} alkoxy substituted by one or more fluorine atoms, $O(CH_2)_nCO_2C_{1-4}$ alkyl, $O(CH_2)_nSC_{1-4}$ alkyl, $O(CH_2)_nNR^4R^5$, $O(CH_2)_nSC_{1-4}$ alkyl or $O(C)_nNR^4R^5$ or, when $O(C)_nNR^4R^5$ or, when

10

15

25

In another aspect the invention provides a process for preparing another group of compounds (group A1) wherein R^0 is F, methyl, C_{1-2} alkoxy, $OCHF_2$, or $O(CH_2)_nNR^4R^5$; R^1 is methylsulphonyl, $OCHF_2$, $O(CH_2)_nCO_2C_{1-4}$ alkyl, $O(CH_2)_nSCH_3$, $(CH_2)_nNR^4R^5$, $(CH_2)_nSCH_3$ or $C(O)NR^4R^5$ or, when R^0 is methyl, C_{1-2} alkoxy, $OCHF_2$, or $O(CH_2)_nN(CH_3)_2$, may also be H; R^2 is H; R^3 is methyl or NH_2 ; R^4 and R^5 are both methyl or, together with the nitrogen atom to which they are attached, form a 5 - 6 membered saturated ring; and n is 1 - 2.

In another aspect the invention provides a process for preparing a compound of formula (I) within group (group A2) wherein R^0 is F, C_{1-3} alkoxy or C_{1-3} alkoxy substituted by one or more fluorine atoms; R^1 is C_{1-4} alkylsulphonyl, C_{1-4} alkoxy substituted by one or more fluorine atoms or, when R^0 C_{1-3} alkoxy or C_{1-3} alkoxy substituted by one or more fluorine atoms, may also be H; R^2 is H; and R^3 is methyl or NH_2 .

In another aspect the invention provides a process for preparing a compound of formula (I) within groups A, A1 and A2, wherein R^0 is preferably at the 3- or 4-position of the phenyl ring and R^2 is at the 6-position of the pyridazine ring.

In another aspect the invention provides a process for preparing the compound 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine and pharmaceutically acceptable derivatives thereof.

Compounds of formula (II), including derivatives corresponding to pharmaceutically acceptable derivatives of formula (I), may be prepared by any method known in the art for the preparation of compounds of analogous structure.

The present invention provides a particularly advantageous process for the preparation of compounds of formula (II), as illustrated in Scheme 1 that follows. The reaction conditions and reagents mentioned in Scheme 1 are by way of example only. In scheme 1, R⁰ to R³ are as defined for formula (I) above; Ph is phenyl; and X is a counterion.

6

Ref 1 H. Zimmer, J.P. Bercz, Liebigs Ann. Chem. **1965**, 686, 107-114, incorporated herein by reference.

- Ref 2 Friedel Crafts acylation in the presence of a Lewis acid (e.g. AICI₃).
 - Ref 3 Suitable inorganic bases include alkali hydroxides (e.g. NaOH); suitable organic bases include amines (e.g. N,N,N,N-tetramethylethylenediamine).

It will be appreciated by those skilled in the art that the imines of formula (III) prepared from the ethanones of formula (V) need not necessarily be isolated and may be employed *in situ* in the preparation of compounds of formula (II).

The compounds of formula (II) themselves need not necessarily be isolated and may be employed *in situ* in the preparation of compounds of formula (I), as described hereinabove.

Counterion X in the N-aminopyridazinium salts of formula (IV) is conveniently a halide (e.g. I) or, more preferably, hexafluorophosphate (PF $_6$). N-Aminopyridazinium hexafluorophosphate salts of formula (IV) are novel and their use according to Scheme 1 is surprisingly advantageous. Thus N-aminopyridazinium hexafluorophosphate salts of formula (IV) are easily prepared and enable the conversion of ethanones of formula (V) to compounds of formula (II) via imines of formula (III) to proceed easily and in high yield.

Accordingly, in a further aspect the invention provides N-aminopyridazinium hexafluorophosphate salts of formula (IV) wherein R⁰ to R³ are as defined for formula (I) above, in particular N-aminopyridazinium hexafluorophosphate.

It will be appreciated by those skilled in the art that compounds of formula (II) may exist as a number of isomers, for example, as follows:

20

5

10

15

20

It will be further appreciated by those skilled in the art that such isomers may under certain conditions exist as an equilibrating mixture.

It will be still further appreciated by those skilled in the art that the compounds of formula (II) contain at least one chiral centre, designated by * therein, and that such compounds exist in the form of a pair of optical isomers (i.e. enantiomers).

It is to be understood that the present invention encompasses all isomers of the compounds of formula (II) and pharmaceutically acceptable derivatives thereof, including all positional, geometric, tautomeric, optical and diastereomeric forms, and mixtures thereof (e.g. racemic mixtures).

N-Aminopyridazinium halides of formula (IV) are either known compounds or may be prepared by literature methods such as those described in, for example, Y Kobayashi *et al*, Chem Pharm Bull, (1971), 19(10), 2106-15; T. Tsuchiya, J. Kurita and K. Takayama, Chem. Pharm. Bull. 28(9) 2676-2681 (1980); and K Novitskii *et al*, Khim Geterotskil Soedin, 1970 2, 57-62; all incorporated herein by reference.

N-Aminopyridazinium hexafluorophosphates of formula (IV) may be prepared by reacting the corresponding N-aminopyridazinium sulphate with hexafluorophosphoric acid or a suitable salt thereof (e.g. potassium hexafluorophosphate or ammonium hexafluorophosphate). The aforementioned sulphates may be prepared from pyridazine by conventional means.

Compounds of formula (VII) are either known compounds or may be prepared by literature methods such as those described in, for example, H Forrest, A Fuller, J Walker, J Chem Soc., 1948, 1501; R Dohmori, Chem Pharm Bull., 1964, (12), 591; and R Bromilow, K Chamberlain, S Patil, Pestic. Sci., 1990, (30), 1.

Compounds of formulae (VI), (VIII) and (X) are either known compounds or may by prepared from known compounds by conventional chemistry.

As will be appreciated by those skilled in the art it may be necessary or desirable at any stage in the synthesis of compounds of formula (I) to protect one or more sensitive groups in the molecule so as to prevent undesirable side reactions.

10

15

20

25

The protecting groups used in the preparation of compounds of formula (I) may be used in conventional manner. See, for example, those described in 'Protective Groups in Organic Synthesis' by Theodora W. Green and Peter G M Wuts, second edition, (John Wiley and Sons, 1991), incorporated herein by reference, which also describes methods for the removal of such groups.

Certain intermediates described above are novel compounds, and it is to be understood that all novel intermediates herein form further aspects of the present invention. Compounds of formula (II), (III) and (V), especially those compounds wherein R⁰ is ethoxy, R¹ and R² are H, and R³ is methyl, are key intermediates and represent a particular aspect of the present invention.

Conveniently, compounds of formula (I) are isolated following work-up in the form of the free base. Pharmaceutically acceptable acid addition salts of the compounds of formula (I) may be prepared using conventional means.

Solvates (e.g. hydrates) of a compound of formula (I) may be formed during the work-up procedure of one of the aforementioned process steps.

When a particular isomeric form of a compound is desired the required isomer may conveniently be separated using preparative high performance liquid chromatography (h.p.l.c.).

The following Examples illustrate, but do not in any way limit, the invention. All temperatures are in 0 C. Flash column chromatography was carried out using Merck 9385 silica. Thin layer chromatography (Tlc) was carried out on silica plates. NMR was carried out on a Bruker 400MHz spectrometer, unless otherwise stated. Chemical shifts are given, with respect to tetramethylsilane as internal chemical shift reference, in δ ppm. The following abbreviations are used: Me, methyl; Et, ethyl; Ph, phenyl; IMS, industrial methylated spirits; TMEDA, N,N,N,N-tetramethylethylenediamine; DCM, dichloromethane; TFA, trfluoroacetic acid; s, singlet; d, doublet; t, triplet and m, multiplet.

10

Example 1

5

10

N-Aminopyridazinium hexafluorophosphate

A solution of hydroxylamine-O-sulfonic acid (73.4g) in water (80mL) and a separate solution of potassium carbonate (65.5g) in water (80mL) were added concurrently dropwise to a solution of pyridazine (40.0g) in water (120mL) at 50°C, maintaining a reaction mixture pH of 3.5-4.0. The reaction mixture was then heated at 40°C for 2 hours to give a solution of N-aminopyridazinium sulfate, which was subsequently cooled to 20°C and filtered. The filtrate was added dropwise to a solution of potassium hexafluorophosphate (91.9g) in water (460mL) at 50°C. The resulting suspension was slowly cooled to 5°C over a 2 hour period, stirred for 30 minutes and the product isolated by filtration. The filtercake was washed portionwise with water (320mL) and the product dried *in vacuo* at 40°C to give the title compound as a white crystalline solid (69.9g, 58%).

¹H-NMR (CDCl₃); $\delta 8.11(1H)$ m, J=8.4Hz, J=5.4Hz; $\delta 8.46(1H)$ m, J=8.4Hz, J=6.4Hz; $\delta 9.09(1H)$ d, J=6.4Hz; $\delta 9.24(1H)$ m, J=5.4Hz; $\delta 9.84(2H)$ s. ¹⁹F-NMR (CDCl₃); $\delta 70.55$ (6F, PF₆⁻) d, J_{P-F} =711Hz.

Example 2

20 N-Aminopyridazinium hexafluorophosphate

By using ammonium hexafluorophosphate (50.9g) in water (50mL), the <u>title</u> <u>compound</u> was obtained as a white crystalline solid (51.7g, 68.7% based on pyridazine) in the manner of Example 1 and was spectroscopically identical thereto.

Example 3

25

30

N-Aminopyridazinium hexafluorophosphate

By using a 60%w/w aqueous solution of hexafluorophosphoric acid (15.2g), the <u>title compound</u> was obtained as a white crystalline solid (10.4g, 68.8% based on pyridazine) in the manner of Example 1 and was spectroscopically identical thereto.

Example 4

5

10

15

20

1-(4-Ethoxyphenyl)-2-[4-(methylsulfonyl)phenyl]ethanone

To a stirred suspension of 4-methylsulfonylphenylacetic acid ¹ (10g) in DCM (80mL) was added dimethylformamide (0.18 mL). The mixture was heated to 30°C, treated with thionyl chloride (3.6mL) and stirred for 1¹/₂ hours. The resulting solution was cooled to 15°C, treated with granular aluminium chloride (11.8g) and stirred for further 15 minutes. Ethoxybenzene (7.1mL) was added and the resultant mixture was warmed to 20°C and stirred for 2 hours. The reaction mixture was cooled to 10°C and treated dropwise with IMS (17mL). The mixture was then diluted with DCM (120mL) and water (60mL) was then added over 20 minutes. The mixture was warmed to 30°C and the layers separated. The organic layer was washed with 5M hydrochloric acid (2x40 mL), saturated sodium bicarbonate solution (40 mL) and then concentrated by distillation at atmospheric pressure to 40 mL. The mixture was cooled to 22°C and aged for 18 hours. The product was isolated by filtration, washed with DCM:iso-octane (1:1, 2x20mL) and dried *in vacuo* at 40°C to give the title compound as a white crystalline solid (10.3g, 69%). MH⁺ 319

 1 H-NMR (CDCl₃) δ : 7.98(m, J=9.1Hz, 2H, 2x p-di-substituted aromatic CH); 7.91(m, J=8.5Hz, 2H, 2x p-di-substituted aromatic CH); 7.47(m, J=8.5Hz, 2H, 2x p-di-substituted aromatic CH); 6.95(m, J=9.1Hz, 2H, 2x p-di-substituted aromatic CH); 4.34(s, 2H, CH₂); 4.12(q, J=7.2Hz, 2H, ethoxy-CH₂); 3.05(s, 3H, CH₃); 1.45(t, J=7.2Hz, 3H, ethoxy-CH₃).

Ref 1: H Forrest, A Fuller, J Walker, J Chem Soc., 1948, 1501

Example 5

A solution of 1-(4-ethoxyphenyl)-2-[4-(methylsulfonyl)phenyl]ethanone (0.5g) in DCM (10mL) was treated with triethylamine (0.22mL) followed by titanium tetrachloride (0.52mL). To the resultant deep red solution was added N-aminopyridazinium iodide ¹ (0.26g) and the mixture was heated under reflux for 18 hours. The reaction mixture was cooled to about 20°C and treated dropwise with water (5mL). The organic phase was washed with sodium hydroxide solution (2N, 5mL), concentrated to dryness and a sample of the resulting crude solid analysed by HPLC-NMR.

Ref: 1 Y Kobayashi et al, Chem Pharm Bull, (1971) 19(10), 2106-15

10

15

20

12

Column	Inertsil ODS-2 20cm x 0.46cm (5μM)		
Flow rate	1 mL/minute		
Detection	UV and NMR (Bruker DRX600 NMR Spectrometer)		
Time (min)	MeCN + 0.05% v/v TFA (%)	$D_2O + 0.05\% \text{ v/v TFA } (\%)$	
0	10	90	
10	10	90	
20	90	10	
25	90	10	
26	10	90	

Two peaks were observed and characterised as follows:

a) Rt 9.74 min: The imine of formula (III) wherein R^0 is OEt, R^1 and R^2 are H and R^3 is Me:

¹H-NMR (MeCN/D₂O) δ 9.45(1H) d, J=6Hz; δ 9.36(1H) d,J=6Hz; δ 8.60(1H) m, J=8Hz, J=6Hz; δ 8.44(1H) m,J=8Hz, J=6Hz; δ 8.03(2H) d, J=8.2Hz; δ 7.79(2H) d, J=8.2Hz; δ 7.42(2H) d, J=8.2Hz; δ 7.05(2H) d, J=8.2Hz; δ 4.28(2H) s; δ 4.13(2H) q,J=7.0Hz; δ 3.12(3H) s; δ 1.35(3H) t, J=7.0Hz; M 396

b) Rt 15.17 min: 2-(4-Ethoxyphenyl)-3-(4-methanesulfonyl-phenyl)-3,3a-dihydro-pyrazolo[1,5-b]pyridazine

(co-elutes with 1-(4-ethoxyphenyl)-2-[4-(methylsulfonyl)phenyl]ethanone) $^{1}\text{H-NMR}$ (CH₃CN/D₂O) $\delta 8.02$ (2H) d, J=8.8Hz; $\delta 7.87$ (2H) d, J=7.6Hz; $\delta 7.51(2\text{H})$ d, J=7.6Hz; $\delta 7.02$ (2H) d, J=8.8Hz; $\delta 6.72$ (1H) m; $\delta 5.85$ (1H) m; $\delta 4.87$ (1H) d, J=10.6Hz; $\delta 4.69$ (1H) m; $\delta 4.12$ (2H) q, ethyl (partially obscured under water peak); $\delta 3.12$ (3H) s; $\delta 1.37$ (3H) t, J=7.0Hz; MH $^{+}$ 396.

The skilled artisan will appreciate that the <u>title compound</u> may under certain conditions exist as an equilibrating mixture (discussed above on pages 7 & 8).

13

Example 6

2-(4-Ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine
(i) 2-(4-Ethoxyphenyl)-3-(4-methanesulfonyl-phenyl)-3,3a-dihydro-pyrazolo[1,5-b]pyridazine

A solution of 1-(4-ethoxyphenyl)-2-(4-methanesulfonyl-phenyl)-ethanone (0.25g) in DCM (5mL) was treated with triethylamine (0.11mL) followed by titanium tetrachloride (0.26mL). To the resultant deep red solution was added N-aminopyridazinium iodide (0.26g) and the mixture was heated under reflux for 18 hours. The reaction mixture was cooled to 20°C and treated dropwise with water (5mL). The organic phase was separated, washed with sodium hydroxide solution (2N, 5mL) and concentrated *in vacuo* to dryness. A sample of the residue was analysed by mass spectrometry, displaying a single major component, MH⁺ 396, corresponding to the title compound. The skilled artisan will appreciate that the title compound may under certain conditions exist as an equilibrating mixture (discussed above on pages 7 and 8).

(ii) 2-(4-Ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine The residue from Example 6(i), 2-(4-ethoxyphenyl)-3-(4-methanesulfonyl-phenyl)-3,3a-dihydro-pyrazolo[1,5-b]pyridazine, was redissolved in DCM (5mL) and palladium on carbon (10%wt, 0.25g) was added. The mixture was heated under reflux for 18 hours, whereupon analysis of the mixture by mass spectrometry showed the presence of a main component, MH⁺ 394, corresponding to the title compound. The reaction mixture was purified directly by silica gel chromatography (ethyl acetate/cyclohexane 2:1) to give the title compound as a white solid (0.181g, 59%).

MH⁺ 394

20

25

30

¹H-NMR (CDCl₃)δ: 8.30(d of d, J=4.4Hz, J=1.9Hz, 1H, aromatic CH); 7.98(m, J=8.5Hz, 2H, 2x p-di-substituted aromatic CH); 7.91(d of d, J=9.1Hz, J=1.9Hz, 1H, aromatic CH); 7.58(m, J=8.5Hz, 2H, 2x p-di-substituted aromatic CH); 7.55(m, J=8.8Hz, 2H, 2x p-di-substituted aromatic CH); 7.07(d of d, J=9.1Hz, J=4.4Hz, 1H); 6.89(m, J=8.8Hz, 2H, 2x p-di-substituted aromatic CH); 4.06(q, J=7.0Hz, 2H, ethoxy-CH₂); 3.13(s, 3H, CH₃); 1.43(t, J=7.0Hz, 3H, ethoxy-CH₃).

14

Example 7

5

10

15

20

25

30

35

2-(4-Ethoxyphenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine Titanium tetrachloride (12.0mL) was added to a stirred suspension of 1-(4ethoxyphenyl)-2-(4-methanesulfonyl-phenyl)-ethanone N-(10.0a). aminopyridazinium hexafluorophosphate (8.3g) and triethylamine (4.4mL) in DCM (200mL) at 20°C and the reaction mixture heated at 40°C for 4.5 hours. The reaction mixture was cooled to 28°C, treated dropwise with TMEDA (2.4mL) and heated at 40°C for 18h to give a solution of the imine of Example 5(a). The reaction was cooled to 25°C, treated dropwise with further TMEDA (21.3mL) and stirred at 25°C for 3 hours to give a solution of (2-(4-ethoxyphenyl)-3-(4methanesulfonyl-phenyl-3,3a-dihydro-pyrazolo[1,5-b]pyridazine). lodine (8.0g) was added and the reaction mixture stirred at 25°C for 20 hours. IMS (25mL) was added dropwise and the reaction mixture was then concentrated to 16 volumes by distillation at atmospheric pressure. The reaction was cooled to 30°C and then treated with 3.33M hydrochloric acid (150mL). The organic phase was separated and the aqueous phase further extracted with DCM (60mL). The combined organic extracts were treated with charcoal (5g) and concentrated to 5 volumes by distillation at atmospheric pressure. concentrate was diluted with ethyl acetate (200mL) and reconcentrated to 5 volumes by distillation at atmospheric pressure. The concentrate was further diluted with ethyl acetate (150mL), heated to 60°C, filtered through a pad of celite, and the celite filtercake washed with warm ethyl acetate (100mL). The combined filtrate and washes were heated to 60°C, washed with 2M sodium hydroxide (50mL), 20% aqueous sodium thiosulfate (2x50mL), water (2x50mL) and concentrated to 4 volumes by distillation at atmospheric pressure. The slurry was stirred overnight at ambient temperature and then at 5°C for 3.5 hours. The product was isolated by filtration, the filtercake washed with cold ethyl acetate (20mL) and the product dried in vacuo at 45°C to give the title compound as a pale brown crystalline solid (8.8g, 71%). MH⁺ 394 ¹H-NMR (CDCl₃)δ: 8.30(d of d, J=4.4Hz, J=1.9Hz, 1H, aromatic CH); 7.98(m, J=8.5Hz, 2H, 2x p-di-substituted aromatic CH); 7.91(d of d, J=9.1Hz, J=1.9Hz, 1H, aromatic CH); 7.58(m, J=8.5Hz, 2H, 2x p-di-substituted aromatic CH); 7.55(m, J=8.8Hz, 2H, 2x p-di-substituted aromatic CH); 7.07(d of d, J=9.1Hz, J=4.4Hz, 1H); 6.89(m, J=8.8Hz, 2H, 2x p-di-substituted aromatic CH); 4.06(q, J=7.0Hz, 2H, ethoxy-CH₂); 3.13(s, 3H, CH₃); 1.43(t, J=7.0Hz, 3H, ethoxy-CH₃).

15

Example 8

5

10

15

20

25

30

2-(4-Ethoxyphenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine

Titanium tetrachloride (26mL) was added to a stirred suspension of 1-(4ethoxyphenyl)-2-(4-methanesulfonyl-phenyl)-ethanone N-amino-(75.0q)pyridazinium hexafluorophosphate (59.6g) in DCM (1125mL) at about 20°C N-Methyl-pyrrolidinone (23mL) was added and TMEDA (50mL) was added over a period of about 4 hours and the reaction mixture heated at 40°C for 4.5 hours. The reaction mixture was stirred at about 20°C for about 2 hours and further TMEDA (93mL) was added over about 15 minutes. The mixture was stirred for about 18 hours and iodine (63g) was added. After about a further 5 hours, IMS (55mL) was added, followed by 3.3M hydrochloric acid (1125mL) and the layers were separated. The organic extract was further washed with 3.3M hydrochloric acid (375mL), aqueous sodium carbonate solution (20%w/v, 375mL), aqueous sodium thiosulfate solution (20%w/v, 2 x 375mL) and aqueous sodium chloride solution (3%w/v, 2 x 375mL). The organic extract was then concentrated by distillation to a residual volume of about 450mL and iso-octane (about 187mL) was added at about 38°C. The resultant slurry was cooled to about 0-5°C and filtered. The crude product was washed with DCM/iso-octane (1:1, 2 x 150mL) and iso-octane (400mL), dried, and then dissolved in acetone (1200mL). This solution was heated to about 50°C and treated with charcoal (19g) for about 1 hour before filtering. The charcoal was washed with hot acetone (750mL) and the combined filtrates and washings were concentrated by distillation to a residual volume of about 825mL. Further acetone (375ml) was added to the concentrate, which was concentrated again to a residual volume of about 825mL. Maintaining the temperature at about 50°C, water (450mL) was added over about 1 hour, causing the product to crystallise. After cooling the slurry to about 0-5°C the product was isolated by filtration, washed with chilled acetone/water (1:1, 2 x 150mL), and dried in vacuo at 65°C to give the title compound as a pale yellow crystalline solid (63.6g, 68.6%), spectroscopically identical to the product of Example 7.

Example 9

2-(4-Ethoxyphenyl)-3-(4-methanesulfonyl-phenyl)-3,3a-dihydro-pyrazolo[1,5-b]pyridazine

Titanium tetrachloride (3.45mL) was added to a stirred mixture of 1-(4-ethoxyphenyl)-2-(4-methanesulfonyl-phenyl)-ethanone (10.0g), N-aminopyridazinium hexafluorophosphate (7.95g) in dichloromethane (150mL) at about 20°C. N-Methyl-pyrrolidinone (3.0mL) was added at about 20°C. TMEDA (6.7mL) was then added over a period of about 4 hours at about 20°C. After stirring the mixture for about 1 hour, a second portion of TMEDA (12.3mL) was added over about 20 minutes, and the reaction mixture was stirred at about 20°C for about 16 hours.

A sample of the reaction mixture was purified by mass-directed preparative HPLC:

Column:

ODS-2 IK-5; 15 x 2cm (5μm)

15 Detection:

5

10

Mass Spectroscopy (Micromass ZMD spectrometer)

Flow rate:

8mL/min

Temp:

Ambient

	Time (min)	water + 0.04%v/v TFA (%)	MeCN + 0.04%v/v TFA(%)
20	0	50	50
	15	10	90
	25	10	90

Fraction Collection Trigger: m/z = 396 (electrospray ionisation)

25 Fraction Collection Trigger Threshold: 2000 counts

Fractions containing compound exhibiting m/z 396 were combined and evaporated to dryness to give the title compound.

¹H-NMR (CDCl₃) δ7.88 (2H) d, J=8.3Hz; δ7.59 (2H) d, J=8.8Hz; δ7.39(2H) d, J=8.3Hz; δ6.81 (2H) d, J=8.8Hz; δ6.74 (1H) m; δ5.83 (1H) m; δ5.37 (1H) m; δ4.74 (1H) m, δ4.59 (1H) d, J=10.8Hz; δ4.00 (2H) q, J=6.8Hz; δ3.04 (3H) s; δ1.39 (3H) t, J=6.8Hz; MH⁺ 396.

Claims

5

10

15

20

1. A process for the preparation of a compound of formula (I)

$$R^3O_2S$$
 R^1
 R^2
 $N-N$
 N
 N
 N
 N
 N

and pharmaceutically acceptable derivatives thereof in which:

 R^0 is halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkoxy substituted by one or more fluorine atoms, or $O(CH_2)_nNR^4R^5$;

 R^1 and R^2 are independently selected from H, $C_{1\text{-}6}$ alkyl, $C_{1\text{-}6}$ alkyl substituted by one or more fluorine atoms, $C_{1\text{-}6}$ alkoxy, $C_{1\text{-}6}$ hydroxyalkyl, $SC_{1\text{-}6}$ alkyl, C(O)H, $C(O)C_{1\text{-}6}$ alkyl, $C_{1\text{-}6}$ alkylsulphonyl, $C_{1\text{-}6}$ alkoxy substituted by one or more fluorine atoms, $O(CH_2)_nCO_2C_{1\text{-}6}$ alkyl, $O(CH_2)_nSC_{1\text{-}6}$ alkyl, $(CH_2)_nNR^4R^5$, $(CH_2)_nSC_{1\text{-}6}$ alkyl or $C(O)NR^4R^5$; with the proviso that when R^0 is at the 4-position and is halogen, at least one of R^1 and R^2 is $C_{1\text{-}6}$ alkylsulphonyl, $C_{1\text{-}6}$ alkoxy substituted by one or more fluorine atoms, $O(CH_2)_nCO_2C_{1\text{-}6}$ alkyl, $O(CH_2)_nSC_{1\text{-}6}$ alkyl, $O(CH_2)_nSC_{1\text{-}6}$ alkyl, $O(CH_2)_nSC_{1\text{-}6}$ alkyl, $O(CH_2)_nSC_{1\text{-}6}$ alkyl, $O(CH_2)_nSC_{1\text{-}6}$ alkyl, $O(CH_2)_nSC_{1\text{-}6}$ alkyl, $O(CH_2)_nSC_{1\text{-}6}$

R³ is C₁₋₆alkyl or NH₂;

 R^4 and R^5 are independently selected from H, or C_{1-6} alkyl or, together with the nitrogen atom to which they are attached, form a 4 - 8 membered saturated ring; and

n is 1-4;

which comprises oxidising under conventional conditions the corresponding compound, or derivative thereof, of formula (II)

$$R^3O_2S$$
 R^1
 R^2
 $N-N$
 N
 N
 N

wherein R^0 to R^3 are as defined for formula (I) above.

- 2. A process according to claim 1 wherein the compound of formula (II) is prepared by treating an imine of formula (III) with a base and wherein the imine of formula (III) is prepared by reacting an ethanone of formula (V) with an N-aminopyridazinium salt of formula (IV).
- 3. A process according to claim 1 or 2 for the preparation of 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine and pharmaceutically acceptable derivatives thereof which comprises oxidising under conventional conditions the compound of formula (II) that is

- or a corresponding derivative thereof.
 - 4. 2-(4-Ethoxyphenyl)-3-(4-methanesulfonyl-phenyl)-3,3a-dihydro-pyrazolo[1,5-b]pyridazine, or a derivative thereof corresponding to a pharmaceutically acceptable derivative of the compound of formula (I) of which 2-(4-ethoxyphenyl)-3-(4-methanesulfonyl-phenyl)-3,3a-dihydro-pyrazolo[1,5-b]pyridazine is the direct precursor.
 - 5. An imine of formula (III)

20

$$R^3O_2S$$
 R^1
 R^2
 N^2
 N^2

wherein R^0 is at the 4-position and is ethoxy; R^1 and R^2 are H; R^3 is methyl; and X^- is a counterion, or a derivative thereof which corresponds to a pharmaceutically acceptable derivative of the compound of formula (I) of which the imine is a precursor.

- 6. 1-(4-ethoxyphenyl)-2-[4-(methylsulfonyl)phenyl]ethanone or a derivative thereof which corresponds to a pharmaceutically acceptable derivative of the compound of formula (I) of which 1-(4-ethoxyphenyl)-2-[4-(methylsulfonyl)phenyl]ethanone is a precursor.
- 5 7. An N-aminopyridazinium salt of formula (IV)

wherein:

10

 R^1 and R^2 are independently selected from H, $C_{1\text{-}6}$ alkyl, $C_{1\text{-}6}$ alkyl substituted by one or more fluorine atoms, $C_{1\text{-}6}$ alkoxy, $C_{1\text{-}6}$ hydroxyalkyl, $SC_{1\text{-}6}$ alkyl, $C(O)H,\ C(O)C_{1\text{-}6}$ alkyl, $C_{1\text{-}6}$ alkylsulphonyl, $C_{1\text{-}6}$ alkoxy substituted by one or more fluorine atoms, $O(CH_2)_nCO_2C_{1\text{-}6}$ alkyl, $O(CH_2)_nSC_{1\text{-}6}$ alkyl, $(CH_2)_nNR^4R^5$, $(CH_2)_nSC_{1\text{-}6}$ alkyl or $C(O)NR^4R^5$; and X^- is PF_6^- .

8. N-Aminopyridazinium hexafluorophosphate.